Key Takeaways
- Deep agrochem trough, H2 recovery bet: Revenue fell ~25% YoY as the agrochemical cycle hit a multi-quarter low, but management expects volumes to pick up from Q3, driven by customer offtake requests and new molecule ramp-ups.
- Inventory overhang masks future revenue: Inventory days stretched 25-30% because anticipated H1 sales slipped into H2 and new launches added stock; liquidation over the next 2-4 quarters should simultaneously shrink the numerator and grow the denominator.
- Pharma and polymer are the structural shift: Both segments are growing 15%-plus and should contribute over one-quarter to one-third of revenue going forward, with pharma reaching the 20s percentage range in the medium term.
- Balance sheet set to deleverage: Capex is nearly done, no further external debt is needed, and ~₹200 cr of debt repayment is planned in H1 FY26 from pref and warrant proceeds, moving toward a net-cash position.
- What to watch next quarter: Whether the promised H2 volume pickup materializes into revenue, the pace of inventory liquidation, and any concrete working-capital guidance once the offtake ramp-up is visible.
Demand Environment
- Agrochemicals hit a floor: The last four quarters marked the lowest demand from the agrochemical sector in recent memory. Management now sees buoyancy in customer conversations, forecasts, and offtake, with some future purchase orders already received.
- Legacy products bottoming out: Legacy product offtake has been "pretty low" compared to historical averages, but customer signals point to a recovery. The base effect from these trough volumes is part of the H2 growth arithmetic.
- Pharma and polymer decoupled from the cycle: Both segments grew at 15%-plus and are insulated from the agrochemical destocking that dragged overall revenue. Their rising share is the structural offset to agro volatility.
- Japan as a demand anchor: Within two to three years, around one-third of sales are expected to come from Japan, the majority secured through long-term contracts, providing visibility that the spot agro market does not.
Vishal Thakkar: "I would put it very simply, two plus two plus two, two years for getting into LOI, two years from LOI to commercialization, another two years for commercialization to ramp up."
Revenue Drivers & LOI Pipeline
- LOI book building toward ₹1,200-1,400 cr annualized: Over the medium term, products under long-term LOIs are expected to generate that revenue run-rate, with FY25 LOI contribution already at ~20%-plus of total revenue.
- New molecule engine still running: 17 molecules launched in FY24 and three in H1 FY25, with three-plus more planned in coming months. These launches add to inventory before they add to revenue, creating a temporary working-capital drag.
- Fluorination as a moat: 40% of new molecules launched across polymer, pharma, and agrochem in the last 20 years involve chlorine molarity where fluorination applies. Tanfac, one of only four HF manufacturers in India, provides supply-chain assurance; four of the last five LOIs have fluorination as one process.
- Medium-term scale target: Management sees a path to ~₹3,000 cr from the standalone business in three to four years based on the current product portfolio, excluding Tanfac revenues.
- H2 growth built on two legs: Pharma and polymer growing at 15%-plus each, plus agrochemical customers placing higher volumes than the last two to three quarters. No significant price changes are expected.
Vishal Thakkar: "So, we do not see any major competitive intensity on this side."
Inventory & Working Capital
- Inventory buildup is deferred revenue, not obsolescence: Inventory rose because anticipated H1 revenue was pushed into H2 and new molecule launches added stock. The 25% revenue degrowth mechanically inflated inventory-turn days by 25-30%.
- Liquidation math works both sides: As inventory sells, the numerator shrinks and revenue (the denominator) grows. Management expects more representative inventory numbers by end-FY25 and a significant reduction from FY24 levels by FY26.
- Working-capital normalization deferred again: FY25 working capital will be similar to last year; FY26 should see significant improvement. Management declined to guide specific days, saying it will do so in the next two quarters after seeing the volume and revenue offtake ramp-up.
- New LOI contracts at historical cycles: Working-capital cycles on new contracts should return to 2020-2021 levels, not the elevated levels of the recent past. Domestic pharma carries a structurally longer cycle, for which the company receives compensation.[15-16]
Vishal Thakkar: "when I sell it out, that converts into revenue and gets into my denominator as well. So, when you do numerator reduction and denominator addition, you will see that the numbers will start getting more representative."
Margins & Returns
- EBITDA margin holding in guided range: Q2 FY25 EBITDA margin was ~28%, H1 at 25.5%. Management is comfortable guiding 25-27% on a consolidated basis, though it has delivered slightly better.
- ROCE path depends on asset turns: With EBITDA margins in the guided range and an asset turn of more than 1.5x, ROCE should return to meaningful levels, historically high-teens to 20s.
- Hybrid power plant online: A ₹59 cr, 9.2 MW hybrid solar and wind plant was commercialized in October 2024, which should support margin through lower energy costs.
Vishal Thakkar: "So, let's say today in this market I would say 25% to 27% of EBITDA margin that I would be comfortable with guidance. Though we have delivered a little better, but on a consol basis that's kind of a number I would go by."
Balance Sheet & Capex
- Capex cycle winding down: Balance capex will be completed over the next two quarters of FY25. From completion to commercialization, allow six to nine months for trial runs, validation, and large-scale operations.
- Debt reduction path is clear: No further external debt is needed for near-term growth. Capex is done, no cash absorption is expected in working capital, and free cash flow will lower debt. From ~₹1,200 cr of debt, term debt will be largely repaid, leaving a near-net-cash position.
- Tanfac capacity doubled: Capacity expanded from 14,150 MT to 29,730 MT, commissioned from October 2024. Management is not the largest consumer of Tanfac's HF but will be in the top five to six; additional volume can be absorbed.
Technology & New Chemistries
- Fluorination as a growth vector: The fluoropolymer market is ~$8 bn, with ~$3 bn addressable for fluor elastomers and fluoro surfactants. The intermediates market where the company plays is ~$600 mn.
- Photochemistry pipeline emerging: Three to four molecules are in the pipeline using photochemistry technology, adding a new capability layer beyond fluorination.
- Pyridine chemistry in pharma: The company uses pyridine chemistry for manufacturing products going into pharma applications; it does not manufacture pyridine itself but works with other classes of pyridine.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue recovery | Numbers to be better from Q3 with increased pharma and polymer contribution | Q3 FY25 |
| Growth normalization | FY26 should return to the growth journey seen in the past | FY26 |
| Inventory normalization | Inventory numbers similar to historical levels around FY21, FY23 | Next 18-24 months |
| Inventory liquidation | Inventory to get liquidated, significant reduction from FY24 levels | Next 2-4 quarters; meaningfully by FY26 |
| Capex completion | Balance capex to be completed | Next two quarters (FY25) |
| Debt repayment | ~₹200-plus cr repaid from pref and warrant proceeds; term debt largely done | H1 FY26 |
| Working capital improvement | Significant improvement vs FY25 | FY26 |
| Japan revenue share | ~1/3 of sales from Japan, majority under long-term contracts | Within 2-3 years |
| LOI annualized revenue | ₹1,200-1,400 cr from LOI products | Medium term |
| Standalone revenue target | ~₹3,000 cr from standalone business based on current portfolio | Medium term (3-4 years) |
| Pharma revenue contribution | In the 20s percentage range | Medium term |
| EBITDA margin | 25-27% on consolidated basis | Ongoing |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Operating revenue | ₹294 cr, 16% higher than Q1 FY25 and ~25% lower than Q2 FY24 |
| H1 FY25 operating revenue | ₹548 cr, ~30% down vs same period last financial year |
| EBITDA including other income | ₹82 cr, down 26% YoY from ₹111 cr in Q2 FY24 |
| EBITDA margin | 28%, vs 28% in Q2 FY24 |
| H1 FY25 EBITDA margin | 25.5% |
| Profit after tax | ₹31 cr, degrowth of 37% YoY from ₹49 cr |
| PAT margin | ~10% of top line |
| H1 FY25 PAT | ₹43 cr, degrowth of 58% YoY from ₹101 cr |
| Top 10 customer concentration | 91% of revenue |
| CAPEX completed as of Sep 30, 2024 | ₹610 cr, remaining to be completed over next two quarters in FY25 |
| Total LOI value | ~₹9,000 cr, implying ₹1,400–1,500 cr revenue over average 5–6 year contract period |
| Annualized revenue expectation from LOI products | ₹1,200–1,400 cr over the next medium term |
| Tanfac plant capacity | 29,730 MT, expanded from 14,150 MT and commissioned from October 2024 |
| Green energy share of electricity needs | 65%, from combined 27.1 MW hybrid power projects saving ~₹28 cr annually |
| Standalone net debt | ~₹1,200 cr as of September 2024 |